Pediatrics

Phakomatoses: Surveillance for the High-Stakes Lesion

Fellowship-level neuroradiology teaching by E. Brooke Schrickel, MD. Open this topic in the interactive reading room →

Core clinical idea

Phakomatoses are surveillance diseases — the read is rarely making the diagnosis but finding the specific high-stakes lesion each syndrome screens for and flagging the one that turned malignant or surgical. Anchor on the pathognomonic finding, hunt that target, and report the change that drives management: a growing optic glioma (NF1), a SEGA obstructing the foramen of Monro (TS), extent of pial enhancement (Sturge-Weber), a hemangioblastoma that flags renal cell carcinoma (VHL), bilateral vestibular schwannomas (NF2).

Bottom line

Each phakomatosis screens for a specific high-stakes lesion — anchor on the pathognomonic finding, hunt that target, and report the change (growing optic glioma, SEGA at the foramen, RCC in VHL).

Core workstation questions

Which syndrome's high-stakes target am I hunting on this study?
NF1: is the optic pathway enlarged, and is any central T2 focus growing or persisting into adulthood (superimposed neoplasm)?
TS: is there an enhancing/enlarging nodule at the foramen of Monro (SEGA), and is the ventricle obstructing?
Sturge-Weber: how extensive are the pial enhancement and hemiatrophy, beyond the tram-track calcification?
VHL: is there a cyst-plus-pial-mural-nodule hemangioblastoma, and has the abdomen been screened for RCC and pheochromocytoma?
NF2: are there bilateral IAC masses, and has the whole spine/neuraxis been covered?

What changes reporting / management

Report optic nerve/chiasm/tract caliber and signal on every NF1 brain; tubular enlargement with T2 signal suggests optic pathway glioma — state stable vs enlarging.
Flag a foramen-of-Monro enhancing/enlarging subependymal nodule as SEGA until proven otherwise, with ventricular size, because it drives a surgical/mTOR decision.
In Sturge-Weber describe the territory and extent of pial enhancement and atrophy (the clinically useful read for seizure burden), not just the presence of calcification.
Treat a cerebellar/cord hemangioblastoma as a flag to evaluate for VHL and screen the body for renal cell carcinoma (and pheochromocytoma if hypertensive).
Bilateral vestibular schwannomas are pathognomonic for NF2 — screen the whole neuraxis for meningiomas, cord ependymoma (often with syrinx), and additional schwannomas; a single young-patient IAC mass earns a contrast spine.

Practical traps

Dismissing a central NF1 T2 focus that is enlarging or persisting into adulthood — that suggests a superimposed low-grade neoplasm, not a benign focus.
Normalizing nodularity along the ventricular margin in TS, where the margin should be smooth and a foramen-of-Monro nodule may be a SEGA.
Confusing cerebellar hemangioblastoma (older, pial-surface nodule, vascular on angiography) with pilocytic astrocytoma (younger, hypovascular), which changes the workup.

Teaching pearls

NF1 foci are central and fade with age; tuberous sclerosis is peripheral/subcortical.
A growing 'NF spot' isn't benign anymore — think superimposed low-grade tumor.
On every NF1 brain, report the optic pathway — glioma is the lesion to protect.
In TS the ventricular margin should be smooth; an enhancing nodule at the foramen of Monro is a SEGA until proven otherwise.
Sturge-Weber: read the extent of pial enhancement and atrophy, not just the tram-track calcification.
A cerebellar cyst with an enhancing pial mural nodule = hemangioblastoma — then go find the renal cell carcinoma.
Bilateral vestibular schwannomas = NF2 — screen the whole neuraxis for meningiomas and cord ependymoma.

Source lectures

Phakomatoses (neurocutaneous syndromes)

Educational material for radiology residents and neuroradiology fellows. Nothing here drives individual patient care, and it contains no patient data.